Compare ARK Genomic Revolution ETF (ARKG) vs Kroger Co (KR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Kroger Co — how do they compare? ARK Genomic Revolution ETF trades at $44.29, while Kroger Co trades at $56.21 (market cap $34.60B). The key difference: Kroger Co pays a 2.55% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Kroger Co nearer its low. Which is the better fit depends on your goals.
| ARKG | KR | |
|---|---|---|
Sector | Sector/Thematic | Consumer Staples |
52-Week High | $44.55 | $75.60 |
52-Week Low | $24.02 | $55.53 |
Market Cap | — | $34.60B |
Enterprise Value | — | $54.70B |
Dividend Yield | — | 2.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG, the ARK Genomic Revolution ETF, trades at $43.04, up 6.06% in the past 24 hours, with a bullish technical signal from moving averages and ADX indicators. The ETF focuses on small- and mid-cap biotech stocks, with its top 10 holdings comprising 59% of the portfolio and a long-term EPS growth rate of 10.7%. Recent news highlights its recovery from a 15% correction, with support emerging at key levels.
The outlook for ARKG is positive, driven by biotech sector tailwinds including a friendlier FDA, strong M&A activity, and AI-driven drug discovery. Risks include high concentration in volatile biotech names and sensitivity to broader market sell-offs. Investors should weigh the growth potential against the inherent volatility of genomics investments.
Kroger (KR) trades at $56.73, down 1.03% with bearish technical signals from moving averages. The company maintains stable revenue around $147B with recent earnings showing mixed results - beating estimates in Q3 and Q4 2025 but missing in Q1 2026. Kroger demonstrates strong cash flow generation with $5.8B from operations in 2025 and pays consistent dividends, while expanding digital services and AI shopping assistance.
Kroger presents a defensive investment opportunity with 2.7% dividend yield and analyst consensus target of $68.63 (21% upside). However, rising debt levels and competitive pressures in grocery retail pose risks. The stock offers value with P/S of 0.25x but trades at premium P/E of 33x, requiring earnings acceleration to justify valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →
